What's Happening?
Avenzo Therapeutics, a clinical-stage biotechnology company, has announced updated results from its Phase 1/2 study of AVZO-021, a selective cyclin-dependent kinase 2 (CDK2) inhibitor. The study, presented at the 2026 American Society of Clinical Oncology
Annual Meeting, focuses on patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The data revealed that AVZO-021 demonstrated clinical activity in heavily pretreated patients, with a median progression-free survival of 5.3 months. The treatment was generally well tolerated, with a low incidence of gastrointestinal and hematologic adverse events. The study included 51 patients with advanced solid tumors and 13 patients with HR+/HER2- breast cancer treated with AVZO-021 in combination with fulvestrant.
Why It's Important?
The development of AVZO-021 is significant as it addresses a critical unmet need in the treatment of HR+/HER2- breast cancer, particularly for patients who have developed resistance to CDK4/6 inhibitors. The promising results suggest that AVZO-021 could become a valuable component of combination treatment strategies, potentially improving outcomes for patients with limited options. The study's findings could influence future treatment protocols and encourage further research into CDK2 inhibitors as a viable therapeutic approach. This development is crucial for the oncology field, as it may lead to more effective treatments for a challenging subset of breast cancer patients.
What's Next?
Avenzo Therapeutics plans to continue evaluating AVZO-021 in combination with AVZO-023, a CDK4 inhibitor, and fulvestrant in the ongoing Phase 1 portion of the ORION-1 Phase 1/2 clinical study. The company aims to further explore the potential of these combination therapies to enhance treatment efficacy and patient outcomes. As the study progresses, Avenzo will likely seek regulatory approval based on the results, which could lead to broader clinical use of AVZO-021. The continued success of these trials could also attract additional investment and partnerships to support the development of next-generation oncology therapies.
